Stockreport

VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer

Vascular Biogenics Ltd. - Ordinary Shares  (VBLT) 
Last vascular biogenics ltd. - ordinary shares earnings: 11/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: vblrx.com
PDF VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03)CA-125 response (GCIG) was repo [Read more]